Key Highlights

  • Second-quarter Revenue reached $124.4 million, up 2% year over year, with GAAP Net Income of $37.8 million, up 11%.
  • Gross Margin expanded to 69% from 55%, driven by ASCENIV revenue growth of 24% to $102.9 million, while BIVIGAM revenue fell 49%.
  • ADMA reiterated full-year 2026 guidance of $530–$560 million in revenue and $265–$300 million in adjusted EBITDA.
  • Shares fell even as the company bought back about 5.3% of shares outstanding year to date, highlighting a disconnect between operating performance and the stock price.

ADMA Biologics (NASDAQ:ADMA), a maker of plasma-derived biologic therapies, fell despite delivering another quarter of strong profitability and expanding margins. The disconnect between the operating performance and the share price frames the question of whether this profitable, growing specialty biologics company can turn sentiment around.

ADMA manufactures and markets FDA-approved plasma-derived products, led by ASCENIV and BIVIGAM for immune-deficiency treatment, along with NABI-HB, and it operates its own plasma-collection centers. Its vertically integrated model and its differentiated, higher-margin ASCENIV product have driven a multi-year improvement in profitability, distinguishing it from many development-stage biotech names.

Latest Developments

In its second-quarter 2026 results, ADMA reported revenue of $124.4 million, up 2% year over year, with GAAP net income of $37.8 million (up 11%) and adjusted EBITDA of $61.8 million (up 22%). Gross margin expanded to 69% from 55%, driven by a favorable product mix. ASCENIV revenue grew 24% to $102.9 million and now dominates the portfolio, while BIVIGAM revenue fell 49% to $19.4 million, a decline the company said was stabilizing sequentially. ADMA reiterated full-year 2026 guidance of $530–$560 million in revenue and $265–$300 million in adjusted EBITDA, and it has been actively repurchasing shares, buying back about 5.3% of shares outstanding year to date.

Financial and Business Position

ADMA's financial profile is unusually strong for a specialty biologics company: growing revenue, robust and expanding margins, solid profitability and meaningful free Cash Flow that it is returning through buybacks. The heavy reliance on ASCENIV is both a strength and a concentration risk, and the sharp BIVIGAM decline bears watching, though management framed it as stabilizing. The company is also advancing a pipeline candidate, SG-001, targeting a sizable market opportunity, with a pre-IND submission anticipated by year-end.

Stock-Market Context

The stock carries a strong-buy rating, reflecting confidence in ADMA's profitable growth, even as the shares have fallen. The turnaround case rests on continued ASCENIV strength, margin expansion, Buybacks and pipeline progress reasserting themselves in the share price; the cautionary case is that concentration in a single product, the BIVIGAM decline and the inherent Supply and pricing dynamics of the plasma-derived industry could temper sentiment despite the strong fundamentals.

What Investors Should Watch

Investors may focus on continued ASCENIV growth and whether BIVIGAM stabilizes, gross-margin and adjusted-EBITDA trends against full-year guidance, plasma-supply dynamics, the pace of share repurchases, and progress on the SG-001 pipeline candidate. Evidence that ADMA can sustain its profitable growth and margin expansion while diversifying its portfolio would do the most to turn the story around after the recent weakness.

A Profitability Story the Market Hasn't Rewarded Yet

ADMA has quietly become one of the more compelling profitability stories in specialty biologics, and the market's failure to reward it recently may reflect concerns about concentration and the plasma industry's cyclicality more than any weakness in execution. The company's success rests heavily on ASCENIV, a differentiated immune globulin that commands strong pricing and margins, and its rapid growth has driven ADMA's gross margin sharply higher while the lower-margin BIVIGAM has declined.

That mix shift is largely favorable for profitability, but it also concentrates the company's fortunes in a single flagship product, which is a genuine risk if competitive or supply dynamics change. ADMA's vertical integration, including its own plasma-collection centers, gives it more control over its supply chain than many peers, an advantage in an industry where plasma availability can constrain growth. With management returning Capital through buybacks and advancing a pipeline candidate, the Investment case rests on sustaining ASCENIV's momentum and margin expansion while gradually diversifying, which would justify a re-rating from current levels.